Patent Term Extended Under 35 U.S.C. 156(e)(2) An order granting an interim extension of the term of the following patent was issued on September 15, 1998. On January 8, 1997, Merck & Co., Inc., the owner of record in the Patent and Trademark Office (PTO) of U.S. Patent No. 4,199,569, filed an application for patent term extension under 35 U.S.C. 156 based upon the regulatory review of the human drug product STROMECTOL (ivermectin). The human drug product STROMECTOL was approved for commercial marketing or use under section 505 of the Federal Food, Drug and Cosmetic Act by the Food and Drug Administration on November 22, 1996. The original term of the patent expired on October 3, 1997, but an interim extension under 35 U.S.C. 156(e)(2) has been granted for a period of one year, i.e, until October 3, 1998. The patent claims the active ingredient ivermectin in the human drug product STROMECTOL and a method of use of ivermectin. An extension of 1,026 days is requested. PTO review of the application to date indicates that the subject patent would be eligible for extension of the patent term under 35 U.S.C. 156. A final determination of the length of the extension of the patent term and issuance of a patent term extension certificate cannot be made until a final determination of the length of the regulatory review period is made by the Food and Drug Administration. Since the term of the patent, as already extended under 35 U.S.C. 156(e)(2), would expire before a certificate of patent term extension can be issued, a second interim extension of the patent term is appropriate. The rights derived from an extension under 35 U.S.C. 156(e), including an interim extension, are limited by 35 U.S.C. 156(b). A second interim extension under 35 U.S.C. 156(e)(2) of the term of U.S. Patent No. 4,199,569 is granted for a period of one year from October 3, 1998, the expiration date of the patent, as extended by the prior one-year interim extension under 35 U.S.C. 156(e)(2). Patent Term Extended Under 35 U.S.C. 156(e)(2) An order granting an interim extension of the term of the following patent was issued on November 9, 1998. SCM Chemicals, Inc., the owner of record in the Patent and Trademark Office (PTO) of U.S. Patent No. 4,209,430, filed an application for patent term extension under 35 U.S.C. 156 on October 23, 1996 (certificate of mailing October 19, 1996), requesting an extension of 1,385 days. The original term of the patent is due to expire on November 24, 1998. The patent claims the food additive "Silvacote K," and a method of use of the food additive "Silvacote K." "Silvacote K" was approved by the Food and Drug Administration for commercial marketing or use on August 31, 1996. In accordance with the limitation of 35 U.S.C. 156(g)(6)(C), applicant is entitled to an extension of at least two years. The initial PTO review of the application to date indicates that the subject patent would be eligible for extension of the patent term under 35 U.S.C. 156. A final determination of the length of the extension of the patent term and issuance of a patent term extension certificate cannot be made until a final determination of the length of the regulatory review period is made. Since the original term of the patent would expire before a certificate of patent term extension can be issued, an interim extension of the patent term is appropriate. An interim extension under 35 U.S.C. 156(e)(2) of the term of U.S. Patent No. 4,209,430 has been granted for a period of one year from the original expiration date of the patent.